Equity Investment Corp Has $141.69 Million Stake in Sanofi (NASDAQ:SNY)

Equity Investment Corp lessened its stake in shares of Sanofi (NASDAQ:SNY) by 0.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 2,458,584 shares of the company’s stock after selling 2,610 shares during the period. Sanofi accounts for about 3.3% of Equity Investment Corp’s investment portfolio, making the stock its 8th biggest holding. Equity Investment Corp owned approximately 0.10% of Sanofi worth $141,688,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Manning & Napier Advisors LLC bought a new stake in Sanofi during the second quarter valued at about $13,725,000. Mount Yale Investment Advisors LLC lifted its position in shares of Sanofi by 44.3% in the first quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock valued at $2,027,000 after acquiring an additional 12,806 shares in the last quarter. GFS Advisors LLC lifted its position in shares of Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after acquiring an additional 11,655 shares in the last quarter. Atria Investments Inc lifted its position in shares of Sanofi by 31.1% in the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock valued at $4,805,000 after acquiring an additional 23,463 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. lifted its position in shares of Sanofi by 15.2% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 116,917 shares of the company’s stock valued at $5,673,000 after acquiring an additional 15,439 shares in the last quarter. Institutional investors own 10.04% of the company’s stock.

Sanofi Price Performance

NASDAQ:SNY opened at $47.97 on Monday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $121.74 billion, a P/E ratio of 24.47, a P/E/G ratio of 1.22 and a beta of 0.61. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The business’s 50-day moving average is $54.65 and its 200 day moving average is $52.23.

Sanofi (NASDAQ:SNY) last posted its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The firm’s revenue for the quarter was up 12.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.55 earnings per share. On average, equities research analysts forecast that Sanofi will post 4.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

SNY has been the topic of several research analyst reports. Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Sanofi presently has a consensus rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.